Travere Therapeutics, Inc. (0001438533) (Filer) — SEC 8-K Filing
Travere Therapeutics
May 11, 2026

Channel-specific outreach playbooks for deal origination.
Comparison posts, methodology, and analysis from the Tentt team.
Monthly market reports on M&A and private equity activity.
Free calculators for M&A, lending, and deal analysis.
Origination in the Age of AI.
Strata Critical Medical, Inc. has closed a secured, asset-based revolving credit facility with JPMorgan Chase Bank for up to $30.0 million in aggregate principal amount. The facility is undrawn at closing and can be increased to $50.0 million, subject to certain conditions.
Strata said the revolving credit facility will improve capital efficiency to fund future acquisitions. The collateral package excludes the company’s owned aircraft, which will remain unencumbered. Strata described a track record of tuck-in acquisitions in the clinical perfusion space.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Travere Therapeutics
May 11, 2026
Pharvaris
May 11, 2026
Partner Therapeutics→Bizengri (bispecific antibody)
May 11, 2026
The Surgery Center of Southern Oregon
May 11, 2026
Mobia Medical
May 11, 2026